Acquisition Opportunity GenIbet Biopharmaceuticals was acquired by Recipharm in January 2022, signaling potential access to a broader CDMO network and expanded manufacturing capabilities that could complement a prospective client’s timeline and scale needs.

Full Suite CAPabilities The company offers end-to-end cGMP production for Drug Substance and Drug Product, master/working cell banks, virus seed stock, cell and gene therapy production, and fill and finish, presenting cross-sell opportunities to biotech and pharma teams seeking a single partner for bench-to-clinic processes.

Specialized Modalities GenIbet focuses on microbial, cell culture, viral propagation, viral vectors, RNA, and microbiome modalities, making it a potential fit for programs in early development and viral vector or gene therapy programs requiring specialized manufacturing expertise.

Local Presence Headquartered in Oeiras, Portugal with cGMP capabilities and proximity to European biopharma clusters, offering a regional manufacturing option to European clients seeking compliant, scalable production without long cross-border logistics.

Size and Growth Potential With 51-200 employees and revenue under $1M, GenIbet represents a growth opportunity for strategic partnerships or investment-led collaborations to scale capabilities, support early-phase programs, and potentially leverage Recipharm’s network post-acquisition.